# Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients

> **NCT02500212** · PHASE4 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 75 (actual)

## Conditions studied

- Organ or Tissue Transplant; Complications

## Interventions

- **DRUG:** ENVARSUS®
- **DRUG:** ADVAGRAF®

## Key facts

- **NCT ID:** NCT02500212
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02500212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02500212, "Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02500212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*